Literature DB >> 24914608

Are we too passive in our attempts to prevent respiratory syncytial virus infection in Northern Canada?

Theo Moraes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24914608      PMCID： PMC4128460          DOI： 10.1155/2014/258504

Source DB:  PubMed          Journal:  Can Respir J        ISSN： 1198-2241            Impact factor:   2.409


× No keyword cloud information.
  13 in total

Review 1.  Viral and host factors in human respiratory syncytial virus pathogenesis.

Authors:  Peter L Collins; Barney S Graham
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

2.  Preventing respiratory syncytial virus infections.

Authors:  Jl Robinson
Journal:  Paediatr Child Health       Date:  2011-10       Impact factor: 2.253

3.  Direct medical costs of bronchiolitis hospitalizations in the United States.

Authors:  Andrea J Pelletier; Jonathan M Mansbach; Carlos A Camargo
Journal:  Pediatrics       Date:  2006-12       Impact factor: 7.124

4.  Prevention of respiratory syncytial virus infection.

Authors:  L Samson
Journal:  Paediatr Child Health       Date:  2009-10       Impact factor: 2.253

5.  Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants.

Authors: 
Journal:  Pediatrics       Date:  1998-09       Impact factor: 7.124

6.  Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn.

Authors: 
Journal:  Pediatrics       Date:  1998-11       Impact factor: 7.124

7.  The real-life effectiveness of palivizumab for reducing hospital admissions for respiratory syncytial virus in infants residing in Nunavut.

Authors:  Anna Banerji; Vladimir Panzov; Michael Young; Bonita E Lee; Muhammad Mamdani; B Louise Giles; Marguerite Dennis; Johanne Morel; Danny Bisson; Bosco A Paes; Charles Hui; Jim Mahony
Journal:  Can Respir J       Date:  2013-12-23       Impact factor: 2.409

8.  Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000.

Authors:  Shelah Leader; Kimmie Kohlhase
Journal:  J Pediatr       Date:  2003-11       Impact factor: 4.406

9.  Comparison of the cost of hospitalization for respiratory syncytial virus disease versus palivizumab prophylaxis in Canadian Inuit infants.

Authors:  Anna Banerji; Krista L Lanctôt; Bosco A Paes; Shababa T Masoud; Derrick Y Tam; W Alexander Macdonald; Ann Roberts
Journal:  Pediatr Infect Dis J       Date:  2009-08       Impact factor: 2.129

Review 10.  Prevention of serious respiratory syncytial virus-related illness. I: Disease pathogenesis and early attempts at prevention.

Authors:  Jessie R Groothuis; J Michael Hoopes; Val G Hemming Jessie
Journal:  Adv Ther       Date:  2011-02-04       Impact factor: 3.845
View more
  1 in total

1.  Burden of Respiratory Syncytial Virus Hospitalizations in Canada.

Authors:  Ian Mitchell; Isabelle Defoy; ElizaBeth Grubb
Journal:  Can Respir J       Date:  2017-11-07       Impact factor: 2.409
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.